A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma

NCT07493135 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

BIOLOGICAL: IMV102 treatment

Sponsor

Suzhou Immunofoco Biotechnology Co., Ltd